Early pregnancy protein multiplex screening reflects circulating and urinary divergences associated with the development of preeclampsia

Background: Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to im...

Full description

Saved in:
Bibliographic Details
Published inHypertension in pregnancy Vol. 37; no. 1; pp. 37 - 50
Main Authors Martinez-Fierro, Margarita L, Castruita-De La Rosa, Claudia, Garza-Veloz, Idalia, Cardiel-Hernandez, Rosa M, Espinoza-Juarez, Marcela A, Delgado-Enciso, Ivan, Castañeda-Lopez, Maria E, Cardenas-Vargas, Edith, Trejo-Vázquez, Fabiola, Sotelo-Ham, Elma I, Castañeda-Miranda, Rodrigo, Cid-Baez, Miguel A, Ortiz-Rodriguez, Jose M, Solis-Sanchez, Luis O, Aviles, Angelica Garcia, Ortiz-Castro, Yolanda
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 02.01.2018
Taylor & Francis Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to improve the prognosis of patients with preeclampsia. Objective: To evaluate the preeclampsia predictive value of 34 angiogenic-related proteins. Methods: We performed a nested cohort case-control study of pregnant women. The profile of the 34 proteins was evaluated at 12, 16, and 20 gestational weeks (GWs), using urine/plasma from 16 women who developed preeclampsia and 20 normotensive pregnant controls by Bio-Plex Pro TM Human Cancer Biomarker Panels 1 and 2. Results: The urine concentration of soluble epidermal growth factor receptor (sEGFR), hepatocyte growth factor (HGF), angiopoietin-2 (ANG-2), endoglin (ENG), soluble fas ligand (sFASL), interleukin 6 (IL-6), placental growth factor (PLGF), and vascular endothelial growth factor A (VEGF-A) at 12 GW, prolactin (PRL), ANG-2, transforming growth factor alpha (TGF-α), and VEGF-A at 16 GW, and soluble IL-6 receptor alpha (sIL-6Rα), ANG-2 and sFASL at 20 GW, were different between groups (p < 0.05). The concentration cut-off values calculated in this study for the mentioned proteins, predicted an increased risk to developing preeclampsia in a range of 3.8-29.8 times in the study population. Conclusion: The proteins sEGFR, HGF, ANG-2, sFASL, IL-6, PLGF, VEGF-A, PRL, TGF-α FGF-b, sHER2/Neu sIL-6Rα, ENG, uPA, and insulin-like growth factor binding protein 1 (IGFBP-1), were predictive of the development of preeclampsia and their use as markers for this disease should be considered.
AbstractList Background: Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to improve the prognosis of patients with preeclampsia. Objective: To evaluate the preeclampsia predictive value of 34 angiogenic-related proteins. Methods: We performed a nested cohort case-control study of pregnant women. The profile of the 34 proteins was evaluated at 12, 16, and 20 gestational weeks (GWs), using urine/plasma from 16 women who developed preeclampsia and 20 normotensive pregnant controls by Bio-Plex ProTM Human Cancer Biomarker Panels 1 and 2. Results: The urine concentration of soluble epidermal growth factor receptor (sEGFR), hepatocyte growth factor (HGF), angiopoietin-2 (ANG-2), endoglin (ENG), soluble fas ligand (sFASL), interleukin 6 (IL-6), placental growth factor (PLGF), and vascular endothelial growth factor A (VEGF-A) at 12 GW, prolactin (PRL), ANG-2, transforming growth factor alpha (TGF-α), and VEGF-A at 16 GW, and soluble IL-6 receptor alpha (sIL-6Rα), ANG-2 and sFASL at 20 GW, were different between groups (p < 0.05). The concentration cut-off values calculated in this study for the mentioned proteins, predicted an increased risk to developing preeclampsia in a range of 3.8–29.8 times in the study population. Conclusion: The proteins sEGFR, HGF, ANG-2, sFASL, IL-6, PLGF, VEGF-A, PRL, TGF-α FGF-b, sHER2/Neu sIL-6Rα, ENG, uPA, and insulin-like growth factor binding protein 1 (IGFBP-1), were predictive of the development of preeclampsia and their use as markers for this disease should be considered.
Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to improve the prognosis of patients with preeclampsia. To evaluate the preeclampsia predictive value of 34 angiogenic-related proteins. We performed a nested cohort case-control study of pregnant women. The profile of the 34 proteins was evaluated at 12, 16, and 20 gestational weeks (GWs), using urine/plasma from 16 women who developed preeclampsia and 20 normotensive pregnant controls by Bio-Plex Pro Human Cancer Biomarker Panels 1 and 2. The urine concentration of soluble epidermal growth factor receptor (sEGFR), hepatocyte growth factor (HGF), angiopoietin-2 (ANG-2), endoglin (ENG), soluble fas ligand (sFASL), interleukin 6 (IL-6), placental growth factor (PLGF), and vascular endothelial growth factor A (VEGF-A) at 12 GW, prolactin (PRL), ANG-2, transforming growth factor alpha (TGF-α), and VEGF-A at 16 GW, and soluble IL-6 receptor alpha (sIL-6Rα), ANG-2 and sFASL at 20 GW, were different between groups (p < 0.05). The concentration cut-off values calculated in this study for the mentioned proteins, predicted an increased risk to developing preeclampsia in a range of 3.8-29.8 times in the study population. The proteins sEGFR, HGF, ANG-2, sFASL, IL-6, PLGF, VEGF-A, PRL, TGF-α FGF-b, sHER2/Neu sIL-6Rα, ENG, uPA, and insulin-like growth factor binding protein 1 (IGFBP-1), were predictive of the development of preeclampsia and their use as markers for this disease should be considered.
BACKGROUNDPreeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to improve the prognosis of patients with preeclampsia.OBJECTIVETo evaluate the preeclampsia predictive value of 34 angiogenic-related proteins.METHODSWe performed a nested cohort case-control study of pregnant women. The profile of the 34 proteins was evaluated at 12, 16, and 20 gestational weeks (GWs), using urine/plasma from 16 women who developed preeclampsia and 20 normotensive pregnant controls by Bio-Plex ProTM Human Cancer Biomarker Panels 1 and 2.RESULTSThe urine concentration of soluble epidermal growth factor receptor (sEGFR), hepatocyte growth factor (HGF), angiopoietin-2 (ANG-2), endoglin (ENG), soluble fas ligand (sFASL), interleukin 6 (IL-6), placental growth factor (PLGF), and vascular endothelial growth factor A (VEGF-A) at 12 GW, prolactin (PRL), ANG-2, transforming growth factor alpha (TGF-α), and VEGF-A at 16 GW, and soluble IL-6 receptor alpha (sIL-6Rα), ANG-2 and sFASL at 20 GW, were different between groups (p < 0.05). The concentration cut-off values calculated in this study for the mentioned proteins, predicted an increased risk to developing preeclampsia in a range of 3.8-29.8 times in the study population.CONCLUSIONThe proteins sEGFR, HGF, ANG-2, sFASL, IL-6, PLGF, VEGF-A, PRL, TGF-α FGF-b, sHER2/Neu sIL-6Rα, ENG, uPA, and insulin-like growth factor binding protein 1 (IGFBP-1), were predictive of the development of preeclampsia and their use as markers for this disease should be considered.
Background: Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to improve the prognosis of patients with preeclampsia. Objective: To evaluate the preeclampsia predictive value of 34 angiogenic-related proteins. Methods: We performed a nested cohort case-control study of pregnant women. The profile of the 34 proteins was evaluated at 12, 16, and 20 gestational weeks (GWs), using urine/plasma from 16 women who developed preeclampsia and 20 normotensive pregnant controls by Bio-Plex Pro TM Human Cancer Biomarker Panels 1 and 2. Results: The urine concentration of soluble epidermal growth factor receptor (sEGFR), hepatocyte growth factor (HGF), angiopoietin-2 (ANG-2), endoglin (ENG), soluble fas ligand (sFASL), interleukin 6 (IL-6), placental growth factor (PLGF), and vascular endothelial growth factor A (VEGF-A) at 12 GW, prolactin (PRL), ANG-2, transforming growth factor alpha (TGF-α), and VEGF-A at 16 GW, and soluble IL-6 receptor alpha (sIL-6Rα), ANG-2 and sFASL at 20 GW, were different between groups (p < 0.05). The concentration cut-off values calculated in this study for the mentioned proteins, predicted an increased risk to developing preeclampsia in a range of 3.8-29.8 times in the study population. Conclusion: The proteins sEGFR, HGF, ANG-2, sFASL, IL-6, PLGF, VEGF-A, PRL, TGF-α FGF-b, sHER2/Neu sIL-6Rα, ENG, uPA, and insulin-like growth factor binding protein 1 (IGFBP-1), were predictive of the development of preeclampsia and their use as markers for this disease should be considered.
Author Trejo-Vázquez, Fabiola
Ortiz-Castro, Yolanda
Castruita-De La Rosa, Claudia
Ortiz-Rodriguez, Jose M
Martinez-Fierro, Margarita L
Delgado-Enciso, Ivan
Cid-Baez, Miguel A
Sotelo-Ham, Elma I
Castañeda-Lopez, Maria E
Cardiel-Hernandez, Rosa M
Castañeda-Miranda, Rodrigo
Espinoza-Juarez, Marcela A
Garza-Veloz, Idalia
Solis-Sanchez, Luis O
Aviles, Angelica Garcia
Cardenas-Vargas, Edith
Author_xml – sequence: 1
  givenname: Margarita L
  orcidid: 0000-0003-1478-9068
  surname: Martinez-Fierro
  fullname: Martinez-Fierro, Margarita L
  email: margaritamf@uaz.edu.mx
  organization: Centro de Innovacion Tecnologica e Industrial, Unidad Academica de Ingenieria Electrica. Universidad Autonoma de Zacatecas
– sequence: 2
  givenname: Claudia
  surname: Castruita-De La Rosa
  fullname: Castruita-De La Rosa, Claudia
  organization: Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas
– sequence: 3
  givenname: Idalia
  orcidid: 0000-0002-6307-1696
  surname: Garza-Veloz
  fullname: Garza-Veloz, Idalia
  organization: Centro de Innovacion Tecnologica e Industrial, Unidad Academica de Ingenieria Electrica. Universidad Autonoma de Zacatecas
– sequence: 4
  givenname: Rosa M
  surname: Cardiel-Hernandez
  fullname: Cardiel-Hernandez, Rosa M
  organization: Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas
– sequence: 5
  givenname: Marcela A
  orcidid: 0000-0001-9644-0382
  surname: Espinoza-Juarez
  fullname: Espinoza-Juarez, Marcela A
  organization: Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas
– sequence: 6
  givenname: Ivan
  orcidid: 0000-0001-9848-862X
  surname: Delgado-Enciso
  fullname: Delgado-Enciso, Ivan
  organization: Instituto Estatal de Cancerologia, Servicios de Salud del Estado de Colima
– sequence: 7
  givenname: Maria E
  surname: Castañeda-Lopez
  fullname: Castañeda-Lopez, Maria E
  organization: Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas
– sequence: 8
  givenname: Edith
  orcidid: 0000-0001-5353-0441
  surname: Cardenas-Vargas
  fullname: Cardenas-Vargas, Edith
  organization: Hospital General Zacatecas "Luz González Cosío", Servicios de Salud de Zacatecas
– sequence: 9
  givenname: Fabiola
  surname: Trejo-Vázquez
  fullname: Trejo-Vázquez, Fabiola
  organization: Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas
– sequence: 10
  givenname: Elma I
  surname: Sotelo-Ham
  fullname: Sotelo-Ham, Elma I
  organization: Coordinacion de Investigacion Estatal de la Secretaría de Salud de Zacatecas, Servicios de Salud de Zacatecas
– sequence: 11
  givenname: Rodrigo
  orcidid: 0000-0003-4938-9179
  surname: Castañeda-Miranda
  fullname: Castañeda-Miranda, Rodrigo
  organization: Centro de Innovacion Tecnologica e Industrial, Unidad Academica de Ingenieria Electrica. Universidad Autonoma de Zacatecas
– sequence: 12
  givenname: Miguel A
  orcidid: 0000-0001-7918-0072
  surname: Cid-Baez
  fullname: Cid-Baez, Miguel A
  organization: Centro de Innovacion Tecnologica e Industrial, Unidad Academica de Ingenieria Electrica. Universidad Autonoma de Zacatecas
– sequence: 13
  givenname: Jose M
  orcidid: 0000-0002-8199-8401
  surname: Ortiz-Rodriguez
  fullname: Ortiz-Rodriguez, Jose M
  organization: Centro de Innovacion Tecnologica e Industrial, Unidad Academica de Ingenieria Electrica. Universidad Autonoma de Zacatecas
– sequence: 14
  givenname: Luis O
  orcidid: 0000-0003-2545-4116
  surname: Solis-Sanchez
  fullname: Solis-Sanchez, Luis O
  organization: Centro de Innovacion Tecnologica e Industrial, Unidad Academica de Ingenieria Electrica. Universidad Autonoma de Zacatecas
– sequence: 15
  givenname: Angelica Garcia
  surname: Aviles
  fullname: Aviles, Angelica Garcia
  organization: Hospital General Zacatecas "Luz González Cosío", Servicios de Salud de Zacatecas
– sequence: 16
  givenname: Yolanda
  orcidid: 0000-0002-7555-0213
  surname: Ortiz-Castro
  fullname: Ortiz-Castro, Yolanda
  organization: Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29308696$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUhSNURH_gEUBespnBTuwk3oGqQitVYgNr68a-mbpy7GA7becNeGyczrRLVr46-u451j3n1YkPHqvqI6NbRnv6hdGWMynEtqas2zLOmOTtm-qMiVpsWtqKkzIXZrNCp9V5Sve0kJyLd9VpLRvat7I9q_5eQXR7MkfcefB6nUJG68m0uGxnh08k6Yjord-RiKNDnRPRNurFQV5F8IYs0XqIe2LsA8Ydeo2JQEpBW8hoyKPNdyTfITH4gC7ME_pMwrimonYwzcnC--rtCC7hh-N7Uf3-fvXr8npz-_PHzeW3243mTZ03HMFoAXTskXWMjyOaooiuxpEBcE4H3XaD0NC1euA1GwwV2DYgZQtNI2VzUd0cfE2AezVHO5WPqwBWPQsh7hTEbLVDVeumKymNQd7xmsMwdnJgtcZiD4L3xevzwasc7c-CKavJJo3OgcewJMVkLwvXsTVWHFAdQ0rlkK_RjKq1UPVSqFoLVcdCy96nY8QyTGhet14aLMDXA2D9GOIEjyE6ozLsXYhjLJXapJr_Z_wDVgC1-A
CitedBy_id crossref_primary_10_3389_fphar_2021_663044
crossref_primary_10_1080_00365513_2018_1516892
crossref_primary_10_20883_medical_e984
crossref_primary_10_3390_ijms241612842
crossref_primary_10_4081_ejh_2022_3429
crossref_primary_10_1080_14767058_2019_1597046
crossref_primary_10_1097_HJH_0000000000001808
crossref_primary_10_1684_ecn_2020_0443
crossref_primary_10_1097_AOG_0000000000004171
crossref_primary_10_3390_ijerph18137045
crossref_primary_10_1016_j_ejogrb_2019_05_036
crossref_primary_10_3390_cells10051003
crossref_primary_10_1016_j_preghy_2020_05_003
crossref_primary_10_1016_j_ejogrb_2023_03_012
crossref_primary_10_1371_journal_pone_0267826
Cites_doi 10.1210/jc.2008-0305
10.1083/jcb.60.2.423
10.1081/PRG-120016790
10.1016/j.ijcard.2014.10.168
10.1371/journal.pone.0063368
10.1002/pd.4811
10.3109/10641955.2013.853777
10.3109/00365519209088393
10.1155/2016/3027363
10.1002/uog.13439
10.1001/jama.293.1.77
10.1016/j.placenta.2014.12.006
10.1093/nar/gku989
10.1016/S0014-4827(03)00089-2
10.3109/14767058.2012.722710
10.1002/pd.2660
10.1155/2011/481095
10.1159/000341264
10.1172/JCI17189
10.3109/10641955.2013.798332
10.1073/pnas.1706546114
10.3109/14767050903366119
10.1002/prca.201400092
10.1161/HYPERTENSIONAHA.110.164285
10.1155/2012/481520
10.1177/1358836X0100600406
10.1038/sj.ki.5000075
10.1111/j.1540-8159.1987.tb04516.x
10.1016/j.ejogrb.2012.10.011
10.3892/etm.2015.2280
10.1016/j.medici.2016.11.008
10.5468/ogs.2015.58.1.10
10.1016/j.placenta.2014.07.001
10.1515/CCLM.2004.026
10.3109/10641950109152635
10.1016/0378-4274(92)90205-X
10.1186/s12884-015-0608-y
10.3109/10641955.2013.827203
10.1080/10641955.2016.1218502
10.1371/journal.pone.0091923
10.1074/jbc.C300012200
10.18869/acadpub.ibj.21.5.312
10.1161/HYPERTENSIONAHA.111.00754
10.1080/10641955.2017.1291673
10.1002/uog.7628
10.1681/ASN.2006090956
10.1016/j.semnephrol.2004.07.008
ContentType Journal Article
Copyright 2018 Taylor & Francis 2018
Copyright_xml – notice: 2018 Taylor & Francis 2018
DBID NPM
AAYXX
CITATION
7X8
DOA
DOI 10.1080/10641955.2017.1411946
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1525-6065
EndPage 50
ExternalDocumentID oai_doaj_org_article_2c37e173de47424abf79b12ce5caa548
10_1080_10641955_2017_1411946
29308696
1411946
Genre Original Articles
Journal Article
GrantInformation_xml – fundername: Consejo Nacional de Ciencia y Tecnología
  grantid: -FOMIX M0024-2013-01-203220; -INFR-254106 and 225520; -SALUD-2010-138721; -SALUD-2012-01-181124; -SEP-CB-2009-01-0128567; SEP-CB-2015-258316
  funderid: 10.13039/501100007350
GroupedDBID ---
00X
03L
0BK
0R~
0YH
29I
36B
4.4
5GY
5RE
AAJNR
AALUX
AAMIU
AAPUL
AAPXX
AAQRR
ABBKH
ABDBF
ABEIZ
ABLKL
ABPTK
ABUPF
ACENM
ACFUF
ACGEJ
ACGFS
ACLSK
ADCVX
ADFCX
ADRBQ
ADXPE
AECIN
AENEX
AEOZL
AEYQI
AFKVX
AFWLO
AGDLA
AGFJD
AGRBW
AIJEM
AIRBT
AJWEG
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AMDAE
BABNJ
BLEHA
BOHLJ
CCCUG
CS3
DKSSO
DU5
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
H13
HZ~
J.N
KRBQP
KSSTO
KWAYT
KYCEM
M4Z
O9-
P2P
RNANH
RVRKI
SV3
TFDNU
TFL
TFW
TUS
UEQFS
V1S
~1N
.GJ
53G
5VS
AALIY
AAORF
ABJNI
ABLIJ
ABWCV
ABXYU
ABZEW
ACKZS
ADFOM
ADFZZ
AEIIZ
AFLEI
AGYJP
AI.
AJVHN
ALYBC
AWYRJ
BRMBE
CAG
COF
CYYVM
CZDIS
DRXRE
DWTOO
GROUPED_DOAJ
JENTW
LJTGL
M44
NPM
NUSFT
QQXMO
TBQAZ
TDBHL
TERGH
TUROJ
VH1
ZXP
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c432t-4eadc5a0f8e1714ffedead572ef1aa440bc67b5ca76cb421bd05e63a996a33993
IEDL.DBID DOA
ISSN 1064-1955
IngestDate Fri Oct 04 13:11:01 EDT 2024
Fri Aug 16 20:39:47 EDT 2024
Fri Aug 23 04:55:49 EDT 2024
Sat Sep 28 08:51:19 EDT 2024
Tue Jun 13 19:53:49 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Angiogenesis
screening
urine
biomarkers
placenta
cancer
preeclampsia
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c432t-4eadc5a0f8e1714ffedead572ef1aa440bc67b5ca76cb421bd05e63a996a33993
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-2545-4116
0000-0002-8199-8401
0000-0002-6307-1696
0000-0003-4938-9179
0000-0002-7555-0213
0000-0001-9848-862X
0000-0001-9644-0382
0000-0001-7918-0072
0000-0003-1478-9068
0000-0001-5353-0441
OpenAccessLink https://doaj.org/article/2c37e173de47424abf79b12ce5caa548
PMID 29308696
PQID 1989548719
PQPubID 23479
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_2c37e173de47424abf79b12ce5caa548
proquest_miscellaneous_1989548719
crossref_primary_10_1080_10641955_2017_1411946
pubmed_primary_29308696
informaworld_taylorfrancis_310_1080_10641955_2017_1411946
PublicationCentury 2000
PublicationDate 2018-01-02
PublicationDateYYYYMMDD 2018-01-02
PublicationDate_xml – month: 01
  year: 2018
  text: 2018-01-02
  day: 02
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Hypertension in pregnancy
PublicationTitleAlternate Hypertens Pregnancy
PublicationYear 2018
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References CIT0030
CIT0032
CIT0031
CIT0034
CIT0036
CIT0035
CIT0038
CIT0037
Poon LC (CIT0016) 2010; 35
CIT0039
CIT0041
CIT0043
Almasry SM (CIT0033) 2016; 57
CIT0042
CIT0001
CIT0045
CIT0044
CIT0003
CIT0047
CIT0002
CIT0046
CIT0049
CIT0004
CIT0048
CIT0007
CIT0006
CIT0009
CIT0008
CIT0050
Kauma SW (CIT0026) 1999; 84
CIT0051
CIT0010
CIT0012
CIT0011
Garza-Veloz I (CIT0005) 2011; 11
Karakus S (CIT0040)
CIT0014
CIT0013
CIT0015
CIT0018
CIT0017
CIT0019
CIT0021
CIT0020
CIT0023
CIT0022
CIT0025
CIT0024
CIT0027
CIT0029
CIT0028
References_xml – ident: CIT0019
  doi: 10.1210/jc.2008-0305
– ident: CIT0044
  doi: 10.1083/jcb.60.2.423
– ident: CIT0034
  doi: 10.1081/PRG-120016790
– ident: CIT0017
  doi: 10.1016/j.ijcard.2014.10.168
– ident: CIT0022
  doi: 10.1371/journal.pone.0063368
– ident: CIT0050
  doi: 10.1002/pd.4811
– ident: CIT0006
  doi: 10.3109/10641955.2013.853777
– ident: CIT0009
  doi: 10.3109/00365519209088393
– ident: CIT0031
  doi: 10.1155/2016/3027363
– volume: 84
  start-page: 4092
  year: 1999
  ident: CIT0026
  publication-title: J Clin Endocrinol Metab.
  contributor:
    fullname: Kauma SW
– ident: CIT0039
  doi: 10.1002/uog.13439
– ident: CIT0018
  doi: 10.1001/jama.293.1.77
– ident: CIT0025
  doi: 10.1016/j.placenta.2014.12.006
– ident: CIT0028
  doi: 10.1093/nar/gku989
– ident: CIT0036
  doi: 10.1016/S0014-4827(03)00089-2
– ident: CIT0030
  doi: 10.3109/14767058.2012.722710
– ident: CIT0015
  doi: 10.1002/pd.2660
– ident: CIT0001
  doi: 10.1155/2011/481095
– ident: CIT0014
  doi: 10.1159/000341264
– ident: CIT0013
  doi: 10.1172/JCI17189
– ident: CIT0037
  doi: 10.3109/10641955.2013.798332
– ident: CIT0038
  doi: 10.1073/pnas.1706546114
– ident: CIT0043
  doi: 10.3109/14767050903366119
– ident: CIT0004
  doi: 10.1002/prca.201400092
– ident: CIT0010
  doi: 10.1161/HYPERTENSIONAHA.110.164285
– ident: CIT0045
  doi: 10.1155/2012/481520
– ident: CIT0046
  doi: 10.1177/1358836X0100600406
– ident: CIT0049
  doi: 10.1038/sj.ki.5000075
– ident: CIT0002
  doi: 10.1111/j.1540-8159.1987.tb04516.x
– ident: CIT0011
  doi: 10.1016/j.ejogrb.2012.10.011
– ident: CIT0040
  publication-title: Arch Gynecol Obstet.
  contributor:
    fullname: Karakus S
– ident: CIT0027
  doi: 10.3892/etm.2015.2280
– ident: CIT0032
  doi: 10.1016/j.medici.2016.11.008
– ident: CIT0041
  doi: 10.5468/ogs.2015.58.1.10
– ident: CIT0042
  doi: 10.1016/j.placenta.2014.07.001
– ident: CIT0035
  doi: 10.1515/CCLM.2004.026
– volume: 57
  start-page: 681
  year: 2016
  ident: CIT0033
  publication-title: Rom J Morphol Embryol.
  contributor:
    fullname: Almasry SM
– volume: 11
  start-page: 35
  year: 2011
  ident: CIT0005
  publication-title: No association between polymorphisms/haplotypes of the vascular endothelial growth factor gene and preeclampsia. BMC Pregnancy Childbirth.
  contributor:
    fullname: Garza-Veloz I
– ident: CIT0023
  doi: 10.3109/10641950109152635
– ident: CIT0047
  doi: 10.1016/0378-4274(92)90205-X
– ident: CIT0048
  doi: 10.1186/s12884-015-0608-y
– ident: CIT0003
  doi: 10.3109/10641955.2013.827203
– ident: CIT0024
  doi: 10.1080/10641955.2016.1218502
– ident: CIT0007
  doi: 10.1371/journal.pone.0091923
– ident: CIT0012
  doi: 10.1074/jbc.C300012200
– ident: CIT0029
  doi: 10.18869/acadpub.ibj.21.5.312
– ident: CIT0020
  doi: 10.1161/HYPERTENSIONAHA.111.00754
– ident: CIT0051
  doi: 10.1080/10641955.2017.1291673
– volume: 35
  start-page: 662
  year: 2010
  ident: CIT0016
  publication-title: Ultrasound Obstet Gynecol.
  doi: 10.1002/uog.7628
  contributor:
    fullname: Poon LC
– ident: CIT0021
  doi: 10.1681/ASN.2006090956
– ident: CIT0008
  doi: 10.1016/j.semnephrol.2004.07.008
SSID ssj0017445
Score 2.2682602
Snippet Background: Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and...
Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in...
BACKGROUNDPreeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and...
SourceID doaj
proquest
crossref
pubmed
informaworld
SourceType Open Website
Aggregation Database
Index Database
Publisher
StartPage 37
SubjectTerms Angiogenesis
biomarkers
cancer
placenta
preeclampsia
screening
urine
Title Early pregnancy protein multiplex screening reflects circulating and urinary divergences associated with the development of preeclampsia
URI https://www.tandfonline.com/doi/abs/10.1080/10641955.2017.1411946
https://www.ncbi.nlm.nih.gov/pubmed/29308696
https://search.proquest.com/docview/1989548719
https://doaj.org/article/2c37e173de47424abf79b12ce5caa548
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pb9UwDI7QkBAXNH6_AVOQuJY1bZqmxz3gaUIaJybtFjmOi3bpe3rvTYL_gD8bO23HQEK7cKusSrVi1_HnOJ-VekcIGOvoilhBLKxjuAM-UhFjcr2BMsVSLgqff3FnF_bzZXN5a9SX9ISN9MDjwp1UWLdk2jqRZRRnIfZtF02F1CAAp9s5-ppmBlPT-UFr83hixju2MF3TzHd3fHkiMhFJW1fLgcIwjHd_7EqZvP8v6tJ_J6B5I1odqkdTBqlPR80fq3s0PFEPzqcz8qfqZ-Ys1pstfRMyDXlay0hLPfcOftccKhi-8qalWROp2-80Xm0xT_JiIQxJSxEetj90kr6NTNi50zCZkpKW8q3m3FGn301Het3LVwnZyTa7K3imLlafvn44K6Z5CwXautoXlr0KGyh7TzIWve8psaRpK2KrgbVlRNdGXvfWYbSVialsyNXAkAlqSXSeq4NhPdBLpTlsoYcasPNok-182TviZMkmj53zuFDv5_UOm5FWI5iJrXQ2UBADhclAC7UUq9y8LKzYWcC-EiZfCXf5ykJ1t20a9rko0o8TTEJ9hwJvZwcI_AfKsQoMtL7eBek6E9xnuoV6MXrGjZqcTDFm7NzR_1D_lXrIGvlcAKpeq4P99precEq0j8fq_uny43J1nP-CXw5dCnc
link.rule.ids 315,786,790,870,2115,27957,27958
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+pregnancy+protein+multiplex+screening+reflects+circulating+and+urinary+divergences+associated+with+the+development+of+preeclampsia&rft.jtitle=Hypertension+in+pregnancy&rft.au=Margarita+L+Martinez-Fierro&rft.au=Claudia+Castruita-De+La+Rosa&rft.au=Idalia+Garza-Veloz&rft.au=Rosa+M+Cardiel-Hernandez&rft.date=2018-01-02&rft.pub=Taylor+%26+Francis+Group&rft.issn=1064-1955&rft.eissn=1525-6065&rft.volume=37&rft.issue=1&rft.spage=37&rft.epage=50&rft_id=info:doi/10.1080%2F10641955.2017.1411946&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_2c37e173de47424abf79b12ce5caa548
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1064-1955&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1064-1955&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1064-1955&client=summon